Grail’s cancer detection blood test is sparking big investor interest despite a recent stock dip — fueled by early success in catching deadly cancers before symptoms, even if a major trial fell short of its main goal. Though not yet profitable and priced high relative to sales, the company’s direct-to-consumer rollout and potential FDA approval could unlock massive growth, with analysts forecasting revenue to soar from $147M to $281M by 2028. For now, holding may be smarter than selling — especially as the long-term promise of early cancer detection keeps investors watching closely.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
